Multiple myeloma is a difficult and dangerous disease. However, the timely detection of the pathological process and an early start of adequate treatment can achieve favorable results. The use of modern drugs increases survival in patients with multiple myeloma, which in some cases can reach 10 years or more.
Effective treatment is possible only if an accurate diagnosis is established, which is based on the following studies:
- general clinical examination, including complete blood count, urinalysis, and blood chemistry;
- immunological tests;
- CT and MRI;
- bone marrow biopsy followed by microscopic examination of the resulting material.
Current Drugs for Multiple Myeloma
The administration of new highly efficient drugs in combination with symptomatic therapy in many cases allows achieving remission with a relatively low incidence of adverse reactions.
- Lenalidomide belongs to the new generation of immunomodulators. It inhibits the function of abnormal cells of the lymphoid tissue, and activates the antitumor immune defense system.
- Bortezomib is an anticancer drug, the effect of which is associated with impairment of the function and reproduction of abnormal cells.
- Thalidomide has immunomodulatory effect; it enhances the natural mechanisms of antitumor protection.
- Bisphosphonates strengthens the bones, prevents their destruction, and reduces the risk of pathological fractures in patients with multiple myeloma.
The treatment begins in the hospital setting, where the patient is observed by a physician and receives services of the nursing staff in the required volume. The information on the cost of medicines is provided by the professional. The patient is discharged home after improvement and receipt of further recommendations.